Latest Amgen Stories
Brodalumab Meets All Primary and All Key Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, Nov.
Mnemosyne appoints Vanessa King, Ph.D. Chief Executive Officer. Dr.
THOUSAND OAKS, Calif., Nov. 10, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S.
THOUSAND OAKS, Calif., Nov. 6, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will participate at the Credit Suisse Annual Healthcare Conference on Tuesday, Nov.
Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND
Board members to help Cloud Pharmaceuticals further penetrate the cloud-based drug design and development market RESEARCH TRIANGLE PARK, N.C., Nov.
RnRMarketResearch.com adds “Colon Cancer and Ovarian Cancer – Pipeline Review, H2 2014” to its store.
Study Failed to Meet Secondary Endpoint of Overall Survival THOUSAND OAKS, Calif., Nov.
CHICAGO, Oct. 31, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog.
Focusing development on rare autoimmune disorder IgG4-related disease (IgG4-RD) MONROVIA, Calif., Oct. 28, 2014 /PRNewswire/ -- Xencor, Inc.
- Having a loud voice; vociferous; clamorous.
- Of grand or imposing sound.